New Data Investigating Merck’s KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015
Dateline City:
KENILWORTH, N.J.
Data to be Presented Across Multiple Tumor Types for KEYTRUDA and MK-8628 (OTX015), an Investigational BET-Bromodomain Inhibitor
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new data evaluating KEYTRUDA®
(pembrolizumab), the company’s anti-PD-1 therapy, in both advanced
non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma
will be presented as part of the Clinical Trials Plenary Session on
Sunday, April 19 at the American Association for Cancer Research (AACR)
Annual Meeting in Philadelphia, April 18 – 22.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Merck | Mesothelioma | Non-Small Cell Lung Cancer | Pharmaceuticals